BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates - BioCryst Pharma (NASDAQ:BCRX)

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE).

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

The results showed sustained reductions in attack rates and improved quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to Orladeyo.
The analysis stratified all 21 patients by their initial reduction in HAE attack rate from baseline to Week 24 in three groups - Group A (<50 percent attack rate reduction; n=4), Group B (≥50 percent attack rate reduction; n=17), and Group C (≥70 percent attack rate reduction; n=14).
Related: BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo.
A sustained reduction in HAE attack rates was observed from baseline to Week 96 across all three groups of patients.
Group A had a mean decrease of 2.3 attacks/month, Group B had a mean decline of 2.5 attacks/month, and Group C had a mean reduction of 2.6 attacks/month.
At Week 96, median attack rates were 0.0 regardless of baseline attack rate.
Price Action: BCRX shares are down 2.77% at $16.24 during the market session on the last check Thursday.

BCRXBioCryst Pharmaceuticals Inc

$8.39-1.88%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.